Achieve Life Sciences (NASDAQ:ACHV) Receives New Coverage from Analysts at Jonestrading

Jonestrading initiated coverage on shares of Achieve Life Sciences (NASDAQ:ACHVFree Report) in a research note released on Wednesday, Benzinga reports. The brokerage issued a buy rating and a $20.00 price target on the biopharmaceutical company’s stock.

A number of other equities research analysts have also weighed in on the company. Oppenheimer restated an outperform rating and set a $18.00 price objective on shares of Achieve Life Sciences in a research report on Monday, April 1st. Lake Street Capital reduced their price target on Achieve Life Sciences from $19.00 to $11.00 and set a buy rating on the stock in a report on Tuesday, March 5th.

Read Our Latest Report on Achieve Life Sciences

Achieve Life Sciences Trading Down 1.3 %

Shares of Achieve Life Sciences stock opened at $4.51 on Wednesday. The company’s 50 day moving average price is $4.42 and its two-hundred day moving average price is $4.40. Achieve Life Sciences has a fifty-two week low of $3.03 and a fifty-two week high of $10.30. The company has a debt-to-equity ratio of 4.02, a quick ratio of 0.82 and a current ratio of 0.82.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ACHV. Tower Research Capital LLC TRC raised its position in shares of Achieve Life Sciences by 75.6% during the first quarter. Tower Research Capital LLC TRC now owns 3,646 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 1,570 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Achieve Life Sciences by 6.1% during the 1st quarter. Renaissance Technologies LLC now owns 41,600 shares of the biopharmaceutical company’s stock worth $283,000 after purchasing an additional 2,400 shares during the last quarter. State Street Corp lifted its position in shares of Achieve Life Sciences by 26.9% in the 1st quarter. State Street Corp now owns 18,731 shares of the biopharmaceutical company’s stock worth $142,000 after purchasing an additional 3,970 shares during the period. Northern Trust Corp boosted its stake in shares of Achieve Life Sciences by 7.3% in the 3rd quarter. Northern Trust Corp now owns 78,957 shares of the biopharmaceutical company’s stock valued at $340,000 after purchasing an additional 5,379 shares during the last quarter. Finally, Manchester Financial Inc. increased its position in shares of Achieve Life Sciences by 43.9% during the third quarter. Manchester Financial Inc. now owns 18,600 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 5,675 shares during the period. 33.52% of the stock is owned by institutional investors and hedge funds.

About Achieve Life Sciences

(Get Free Report)

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.

Featured Articles

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.